Table 1.

Frequency of breakthrough infection during observation period

	n	Frequency	95% CI (%)
All patients	9417	105 (1.1%)	0.9–1.4
BNT162b2 (2 doses)	6423	78 (1.2%)	1.0–1.5
mRNA-1273 (2 doses)	2993	27 (0.9%)	0.6–1.3
Solid tumor malignancy	6948	68 (1.0%)	0.8–1.2
Hematologic malignancy	1567	25 (1.6%)	1.0–2.4